'Checkpoint blockade treatment' presentation slideshows

Dr. Michael Har-Noy plans to start a pivotal Phase II/III randomized study of AlloStimTM in the therapy of metastatic KRAS gene positive colon tumors. Dr. Michael Har-Noy notes there is no approved third line treatment for these patients. A favorable outcome of this study would likely lead to FDA marketing approval for AlloStimTM. Dr. Michael Har-Noy intends to start the study in the United States as well as two other international sites.

156 views • 5 slides